jaleh gholami eshlaghi md. mph. phd candidate in epidemiology
TRANSCRIPT
![Page 1: Jaleh Gholami Eshlaghi MD. MPH. PhD Candidate in Epidemiology](https://reader030.vdocuments.mx/reader030/viewer/2022032612/56649eb75503460f94bc13f9/html5/thumbnails/1.jpg)
Jaleh Gholami EshlaghiMD. MPH. PhD Candidate in Epidemiology
![Page 2: Jaleh Gholami Eshlaghi MD. MPH. PhD Candidate in Epidemiology](https://reader030.vdocuments.mx/reader030/viewer/2022032612/56649eb75503460f94bc13f9/html5/thumbnails/2.jpg)
آشنایی با اصول کلی که در هنگام انتقال دانش باید در نظر گرفت•آشنایی با برخی از روش های انتقال دانش برای گروه های متفاوت •
مخاطبینآشنایی با روش های موثر انتقال دانش•توجه به اثربخشی روش های انتقال هنگام تدوین استراتژی انتقال•
اهداف آموزشی این بخش
![Page 3: Jaleh Gholami Eshlaghi MD. MPH. PhD Candidate in Epidemiology](https://reader030.vdocuments.mx/reader030/viewer/2022032612/56649eb75503460f94bc13f9/html5/thumbnails/3.jpg)
Message (WHAT?)
Target Audience ( To WHOM?)
Messenger (BY WHOM?)
Evaluation (with what EFFECT should it be transferred?)
Knowledge transfer process and support system (HOW?)
Review
Level of Evidence
Barriers
![Page 4: Jaleh Gholami Eshlaghi MD. MPH. PhD Candidate in Epidemiology](https://reader030.vdocuments.mx/reader030/viewer/2022032612/56649eb75503460f94bc13f9/html5/thumbnails/4.jpg)
Consider the audience:
– the problems audiences face, – the message that is valuable to him/her– the level of detail they need, – the style of thinking they use– the messenger they can trust– the language they are comfortable with
What should be considered?
![Page 5: Jaleh Gholami Eshlaghi MD. MPH. PhD Candidate in Epidemiology](https://reader030.vdocuments.mx/reader030/viewer/2022032612/56649eb75503460f94bc13f9/html5/thumbnails/5.jpg)
مرور نظام مند و متاآناليز كارازمايي هاي باليني شاهد دار تصادفي •شده نشان مي دهد كه ميزان خطر نسبي شكستگي ران براي
-0.89% 95 (با حدود اطمينان 1.1 به تنهايي Dمصرف ويتامين) مي باشد در حالي خطر نسبي شكستگي ران در صورت 1.36
(با حدود اطمينان 0.82 و مكمل كلسيم برابر با Dمصرف ويتامين ) مي باشد.0.94, %0.71 95
در صورت مصرف مكمل كلسيم باعث كاهش خطر Dويتامين • به تنهايي Dشكستگي ران مي شود در صورتي كه مصرف ويتامين
اين تاثير را ندارد.
Example
![Page 6: Jaleh Gholami Eshlaghi MD. MPH. PhD Candidate in Epidemiology](https://reader030.vdocuments.mx/reader030/viewer/2022032612/56649eb75503460f94bc13f9/html5/thumbnails/6.jpg)
Evidence based medicine should be complemented by evidence based
implementation.
Richard Grol
![Page 7: Jaleh Gholami Eshlaghi MD. MPH. PhD Candidate in Epidemiology](https://reader030.vdocuments.mx/reader030/viewer/2022032612/56649eb75503460f94bc13f9/html5/thumbnails/7.jpg)
• Health care Professionals• Patients• Policy makers and managers
strategies focusing:
![Page 8: Jaleh Gholami Eshlaghi MD. MPH. PhD Candidate in Epidemiology](https://reader030.vdocuments.mx/reader030/viewer/2022032612/56649eb75503460f94bc13f9/html5/thumbnails/8.jpg)
![Page 9: Jaleh Gholami Eshlaghi MD. MPH. PhD Candidate in Epidemiology](https://reader030.vdocuments.mx/reader030/viewer/2022032612/56649eb75503460f94bc13f9/html5/thumbnails/9.jpg)
– Printed Educational material (Clinical Practice Guideline, audio-visual materials, and electronic publications)
– Educational Meeting• Didactic meeting (Lectures, Conferences)• Interactive Educational Meeting (workshop)
– Educational Outreach (Prescribing behavior)– Local opinion leaders (Educationally influential
providers)– Audit and feedback (Any summary of Clinical
performance)– Reminders (Patient or encounter specific
information)
strategies focusing on professionals
![Page 10: Jaleh Gholami Eshlaghi MD. MPH. PhD Candidate in Epidemiology](https://reader030.vdocuments.mx/reader030/viewer/2022032612/56649eb75503460f94bc13f9/html5/thumbnails/10.jpg)
• Evidence-based clinical practice guidelines are knowledge tools defined as systematically developed statements that help clinicians and patients make decisions about appropriate health care for specific clinical circumstances.
Clinical Practice Guideline
![Page 11: Jaleh Gholami Eshlaghi MD. MPH. PhD Candidate in Epidemiology](https://reader030.vdocuments.mx/reader030/viewer/2022032612/56649eb75503460f94bc13f9/html5/thumbnails/11.jpg)
![Page 12: Jaleh Gholami Eshlaghi MD. MPH. PhD Candidate in Epidemiology](https://reader030.vdocuments.mx/reader030/viewer/2022032612/56649eb75503460f94bc13f9/html5/thumbnails/12.jpg)
![Page 13: Jaleh Gholami Eshlaghi MD. MPH. PhD Candidate in Epidemiology](https://reader030.vdocuments.mx/reader030/viewer/2022032612/56649eb75503460f94bc13f9/html5/thumbnails/13.jpg)
![Page 14: Jaleh Gholami Eshlaghi MD. MPH. PhD Candidate in Epidemiology](https://reader030.vdocuments.mx/reader030/viewer/2022032612/56649eb75503460f94bc13f9/html5/thumbnails/14.jpg)
How are clinical practice guidelines developed?
• Establish multidisciplinary guideline team• Identify clinical question that explicitly defines the patients,
intervention/exposure, comparisons (if relevant), outcomes of interest and setting
• Conduct a systematic review of evidence• Appraise and interpret evidence and come to consensus on its
meaning• Draft guideline recommendations that align with evidentiary
base• Complete an external review of draft report among intended
users and key stakeholders• Revise the guidelines in response to external review• Read the final guideline report for distribution and dissemination• Prepare implementation strategy
Appraisal of Guidelines Research and Evaluation (AGREE)
![Page 15: Jaleh Gholami Eshlaghi MD. MPH. PhD Candidate in Epidemiology](https://reader030.vdocuments.mx/reader030/viewer/2022032612/56649eb75503460f94bc13f9/html5/thumbnails/15.jpg)
• Opinion leadership is the degree to which an individual is able to influence other individuals’ attitudes or overt behavior informally in a desired way with relative frequency.
Local opinion leaders
![Page 16: Jaleh Gholami Eshlaghi MD. MPH. PhD Candidate in Epidemiology](https://reader030.vdocuments.mx/reader030/viewer/2022032612/56649eb75503460f94bc13f9/html5/thumbnails/16.jpg)
This informal leadership is not a function of the individual’s formal position or status in the system, it is earned and maintained by the individual’s – Technical competence, – social accessibility, and – conformity to the systems norms.
opinion leaders have more:– external communication, – higher social status, – innovative
Local opinion leaders
![Page 17: Jaleh Gholami Eshlaghi MD. MPH. PhD Candidate in Epidemiology](https://reader030.vdocuments.mx/reader030/viewer/2022032612/56649eb75503460f94bc13f9/html5/thumbnails/17.jpg)
• High level of knowledge• Communication skills• Taking into account stakeholders• Professional ethics
Local opinion leaders characteristics in Iran
![Page 18: Jaleh Gholami Eshlaghi MD. MPH. PhD Candidate in Epidemiology](https://reader030.vdocuments.mx/reader030/viewer/2022032612/56649eb75503460f94bc13f9/html5/thumbnails/18.jpg)
G085
G095
G086
G087
G033
G032
G128
G078G116
G090
G027 G147
G150
G049
G069
G140
G051
G050 G099
G047
G048
G053
G007
G141
G013
G009
G001G005
G123
G100
G098
G111
G112
G113
G065 G062 G017
G064G071
G011 G015
G004
G114
G139
G089
G115
G074
Gynaecologists’ social network
18/47
![Page 19: Jaleh Gholami Eshlaghi MD. MPH. PhD Candidate in Epidemiology](https://reader030.vdocuments.mx/reader030/viewer/2022032612/56649eb75503460f94bc13f9/html5/thumbnails/19.jpg)
– Printed Educational material (Clinical Practice Guideline, audio-visual materials, and electronic publications)
– Educational Meeting• Didactic meeting (Lectures, Conferences)• Interactive Educational Meeting (workshop)
– Educational Outreach (Prescribing behavior)– Local opinion leaders (Educationally influential
providers)– Audit and feedback (Any summary of Clinical
performance)– Reminders (Patient or encounter specific
information)
Effectiveness of professional behavior change strategies
![Page 20: Jaleh Gholami Eshlaghi MD. MPH. PhD Candidate in Epidemiology](https://reader030.vdocuments.mx/reader030/viewer/2022032612/56649eb75503460f94bc13f9/html5/thumbnails/20.jpg)
• Patient decision aids• Interactive Health Communication Applications
(Information packages for patients that combine health information with at least one of social support, decision support, or behavior change support)
• Interventions to enhance medication adherence (Instruction, telephone monitoring and counseling, Reminders, special ‘reminder’ pill packaging, …)
strategies focusing on patients
![Page 21: Jaleh Gholami Eshlaghi MD. MPH. PhD Candidate in Epidemiology](https://reader030.vdocuments.mx/reader030/viewer/2022032612/56649eb75503460f94bc13f9/html5/thumbnails/21.jpg)
What are patient decision aids?
Patient decision aids translate evidence into patient-friendly tools to inform patients about their options, help them clarify the value they place on benefits versus harms, and guide them in the process of decision making.
Formats for decision aids are:• paper-based booklets, • video/DVDs,• decision boards, • and internet-based materials
![Page 22: Jaleh Gholami Eshlaghi MD. MPH. PhD Candidate in Epidemiology](https://reader030.vdocuments.mx/reader030/viewer/2022032612/56649eb75503460f94bc13f9/html5/thumbnails/22.jpg)
Ottawa Hospital Research Institute (OHRI)
![Page 23: Jaleh Gholami Eshlaghi MD. MPH. PhD Candidate in Epidemiology](https://reader030.vdocuments.mx/reader030/viewer/2022032612/56649eb75503460f94bc13f9/html5/thumbnails/23.jpg)
presentation of outcome probabilities
![Page 24: Jaleh Gholami Eshlaghi MD. MPH. PhD Candidate in Epidemiology](https://reader030.vdocuments.mx/reader030/viewer/2022032612/56649eb75503460f94bc13f9/html5/thumbnails/24.jpg)
Ottawa PDA format
![Page 25: Jaleh Gholami Eshlaghi MD. MPH. PhD Candidate in Epidemiology](https://reader030.vdocuments.mx/reader030/viewer/2022032612/56649eb75503460f94bc13f9/html5/thumbnails/25.jpg)
clarify patients’ values for outcomes
![Page 26: Jaleh Gholami Eshlaghi MD. MPH. PhD Candidate in Epidemiology](https://reader030.vdocuments.mx/reader030/viewer/2022032612/56649eb75503460f94bc13f9/html5/thumbnails/26.jpg)
![Page 27: Jaleh Gholami Eshlaghi MD. MPH. PhD Candidate in Epidemiology](https://reader030.vdocuments.mx/reader030/viewer/2022032612/56649eb75503460f94bc13f9/html5/thumbnails/27.jpg)
How do we determine the quality of
patient decision aids?
![Page 28: Jaleh Gholami Eshlaghi MD. MPH. PhD Candidate in Epidemiology](https://reader030.vdocuments.mx/reader030/viewer/2022032612/56649eb75503460f94bc13f9/html5/thumbnails/28.jpg)
IPDAS Criteria
![Page 29: Jaleh Gholami Eshlaghi MD. MPH. PhD Candidate in Epidemiology](https://reader030.vdocuments.mx/reader030/viewer/2022032612/56649eb75503460f94bc13f9/html5/thumbnails/29.jpg)
• Patient decision aids• Interactive Health Communication Applications
(Information packages for patients that combine health information with at least one of social support, decision support, or behavior change support)
• Interventions to enhance medication adherence (Instruction, telephone monitoring and counseling, Reminders, special ‘reminder’ pill packaging, …)
Effectiveness of knowledge translation strategies focusing on patients
![Page 30: Jaleh Gholami Eshlaghi MD. MPH. PhD Candidate in Epidemiology](https://reader030.vdocuments.mx/reader030/viewer/2022032612/56649eb75503460f94bc13f9/html5/thumbnails/30.jpg)
Do patient decision aids work?
PDAs improve:
• patients’ participation in decision making,• knowledge of options, • agreement between patients’ values and the
subsequent treatment or screening decisions.• realistic expectations of the chances of benefits,
harms, and side effects• More use of conservative options, • without apparent adverse effects on health outcomes
or anxiety.
![Page 31: Jaleh Gholami Eshlaghi MD. MPH. PhD Candidate in Epidemiology](https://reader030.vdocuments.mx/reader030/viewer/2022032612/56649eb75503460f94bc13f9/html5/thumbnails/31.jpg)
Reader Friendly Writing (1:3:25)
Policy brief
strategies focusing on professionals
![Page 32: Jaleh Gholami Eshlaghi MD. MPH. PhD Candidate in Epidemiology](https://reader030.vdocuments.mx/reader030/viewer/2022032612/56649eb75503460f94bc13f9/html5/thumbnails/32.jpg)
![Page 33: Jaleh Gholami Eshlaghi MD. MPH. PhD Candidate in Epidemiology](https://reader030.vdocuments.mx/reader030/viewer/2022032612/56649eb75503460f94bc13f9/html5/thumbnails/33.jpg)
1:3:251: Main message1: Main message
3: 3: Executive Summary25: The Report
““Reader Friendly Writing” Writing for Reader Friendly Writing” Writing for health policy makers, planners and health policy makers, planners and
managersmanagers
((Canadian Health Service Research Canadian Health Service Research Foundation)Foundation)
![Page 34: Jaleh Gholami Eshlaghi MD. MPH. PhD Candidate in Epidemiology](https://reader030.vdocuments.mx/reader030/viewer/2022032612/56649eb75503460f94bc13f9/html5/thumbnails/34.jpg)
• This part is one page of main message bullets. • They are the heart of your report, the lessons decision
makers can take from your research. • Set aside your text and focus on expressing clear
conclusions based on what you've learned. • Consider your audience - who are they, and what do
they most need to know about what you've learned? • tell decision makers what implications your work has
for theirs.• if you're really not ready to draw more conclusions,
don't just fall back on "more research is needed." Use your main messages to define the questions that still need to be asked.
Main Messages
![Page 35: Jaleh Gholami Eshlaghi MD. MPH. PhD Candidate in Epidemiology](https://reader030.vdocuments.mx/reader030/viewer/2022032612/56649eb75503460f94bc13f9/html5/thumbnails/35.jpg)
• The three in 1:3:25 is the executive summary. • An executive summary is not an academic abstract;
it's much more like a newspaper story, where the most interesting stuff goes at the top, followed by the background and context and less important information further down.
• This is not the place for more than a line or two about your approach, methods and other technical details.
Executive Summary
![Page 36: Jaleh Gholami Eshlaghi MD. MPH. PhD Candidate in Epidemiology](https://reader030.vdocuments.mx/reader030/viewer/2022032612/56649eb75503460f94bc13f9/html5/thumbnails/36.jpg)
• Context• Implications• Approach• Results• Additional Resources• Further Research• References and Bibliography• appendix
The Report
![Page 37: Jaleh Gholami Eshlaghi MD. MPH. PhD Candidate in Epidemiology](https://reader030.vdocuments.mx/reader030/viewer/2022032612/56649eb75503460f94bc13f9/html5/thumbnails/37.jpg)
Policy briefs are a relatively new approach to packaging research
evidence for policymakers.
Policy Brief
![Page 38: Jaleh Gholami Eshlaghi MD. MPH. PhD Candidate in Epidemiology](https://reader030.vdocuments.mx/reader030/viewer/2022032612/56649eb75503460f94bc13f9/html5/thumbnails/38.jpg)
![Page 39: Jaleh Gholami Eshlaghi MD. MPH. PhD Candidate in Epidemiology](https://reader030.vdocuments.mx/reader030/viewer/2022032612/56649eb75503460f94bc13f9/html5/thumbnails/39.jpg)
• Title• Key messages
– What is the problem?– What do we know (and not know) about viable
options to address the problem?– What implementation considerations need to be
borne in mind?• Report
– Introduction that describes the issue and the context in which it will be addressed
– Definition of the problem– Options for addressing the problem, with each one
assessed in a table (an example is shown below)
Possible outline of a policy brief
![Page 40: Jaleh Gholami Eshlaghi MD. MPH. PhD Candidate in Epidemiology](https://reader030.vdocuments.mx/reader030/viewer/2022032612/56649eb75503460f94bc13f9/html5/thumbnails/40.jpg)
![Page 41: Jaleh Gholami Eshlaghi MD. MPH. PhD Candidate in Epidemiology](https://reader030.vdocuments.mx/reader030/viewer/2022032612/56649eb75503460f94bc13f9/html5/thumbnails/41.jpg)
![Page 42: Jaleh Gholami Eshlaghi MD. MPH. PhD Candidate in Epidemiology](https://reader030.vdocuments.mx/reader030/viewer/2022032612/56649eb75503460f94bc13f9/html5/thumbnails/42.jpg)
![Page 43: Jaleh Gholami Eshlaghi MD. MPH. PhD Candidate in Epidemiology](https://reader030.vdocuments.mx/reader030/viewer/2022032612/56649eb75503460f94bc13f9/html5/thumbnails/43.jpg)
• In contrast to the substantial evidence base on the effectiveness of knowledge translation strategies targeting health care professionals and patients, we are not aware of any experimental studies evaluating the effects of knowledge translation research that focused on policy makers or senior health service managers.
Effectiveness of knowledge translation strategies focusing on policy makers and
senior health service managers
![Page 44: Jaleh Gholami Eshlaghi MD. MPH. PhD Candidate in Epidemiology](https://reader030.vdocuments.mx/reader030/viewer/2022032612/56649eb75503460f94bc13f9/html5/thumbnails/44.jpg)
Mass media Continuous medical education Structural modification and support Financial incentives Changing rules and regulations …
Other strategies
![Page 45: Jaleh Gholami Eshlaghi MD. MPH. PhD Candidate in Epidemiology](https://reader030.vdocuments.mx/reader030/viewer/2022032612/56649eb75503460f94bc13f9/html5/thumbnails/45.jpg)
Thank you